Opposite Modulation of the NMDA Receptor by Glycine and S-Ketamine and the Effects on Resting State EEG Gamma Activity: New Insights into the Glutamate Hypothesis of Schizophrenia

• Published in: International journal of molecular sciences Vol. 24; no. 3; p. 1913
• Main Authors: Haaf, Moritz, Curic, Stjepan, Rauh, Jonas, Steinmann, Saskia, Mulert, Christoph, Leicht, Gregor
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.01.2023; MDPI
• Subjects: Antipsychotics; Binding sites; Biomarkers; Clinical trials; Drug therapy; Electroencephalography; Glutamic Acid; Humans; Ketamine; Ketamine - pharmacology; Male; N-Methylaspartate; Psychotropic drugs; Quantitative psychology; Receptors, N-Methyl-D-Aspartate - physiology; Schizophrenia; Schizophrenia - drug therapy; Signal transduction; NMDAR; S-ketamine; γ oscillations; E/I balance; glycine; EEG
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24031913

NMDA-receptor hypofunction is increasingly considered to be an important pathomechanism in schizophrenia. However, to date, it has not been possible to identify patients with relevant NMDA-receptor hypofunction who would respond to glutamatergic treatments. Preclinical models, such as the ketamine model, could help identify biomarkers related to NMDA-receptor function that respond to glutamatergic modulation, for example, via activation of the glycine-binding site. We, therefore, aimed to investigate the effects of opposing modulation of the NMDA receptor on gamma activity (30–100 Hz) at rest, the genesis of which appears to be highly dependent on NMDA receptors. The effects of subanesthetic doses of S-ketamine and pretreatment with glycine on gamma activity at rest were examined in twenty-five healthy male participants using 64-channel electroencephalography. Psychometric scores were assessed using the PANSS and the 5D-ASC. While S-ketamine significantly increased psychometric scores and gamma activity at the scalp and in the source space, pretreatment with glycine did not significantly attenuate any of these effects when controlled for multiple comparisons. Our results question whether increased gamma activity at rest constitutes a suitable biomarker for the target engagement of glutamatergic drugs in the preclinical ketamine model. They might further point to a differential role of NMDA receptors in gamma activity generation.